TEMPOL抑制叙利亚仓鼠模型中SARS-CoV-2的复制及肺部疾病的发展。

TEMPOL inhibits SARS-CoV-2 replication and development of lung disease in the Syrian hamster model.

作者信息

Maio Nunziata, Cherry Sara, Schultz David C, Hurst Brett L, Linehan W Marston, Rouault Tracey A

机构信息

Molecular Medicine Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.

Department of Pathology and Laboratory Medicine, Chemogenomic Discovery Program. University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA.

出版信息

iScience. 2022 Oct 21;25(10):105074. doi: 10.1016/j.isci.2022.105074. Epub 2022 Sep 6.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide outbreak, known as coronavirus disease 2019 (COVID-19). Alongside vaccines, antiviral therapeutics is an important part of the healthcare response to COVID-19. We previously reported that TEMPOL, a small molecule stable nitroxide, inactivated the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 by causing the oxidative degradation of its iron-sulfur cofactors. Here, we demonstrate that TEMPOL is effective in inhibiting viral replication in the Syrian hamster model. The inhibitory effect of TEMPOL on SARS-CoV-2 replication was observed in animals when the drug was administered 2 h before infection in a high-risk exposure model. These data support the potential application of TEMPOL as a highly efficacious antiviral against SARS-CoV-2 infection in humans.